Caffeine
- Generic Name
- Caffeine
- Brand Names
- Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10N4O2
- CAS Number
- 58-08-2
- Unique Ingredient Identifier
- 3G6A5W338E
- Background
Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, whic...
- Indication
Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broa...
- Associated Conditions
- Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain
- Associated Therapies
- Analgesia, Antacid therapy, Athletic Performance
Ibuprofen/Caffeine Lower Back or Neck Pain Study
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 635
- Registration Number
- NCT03003000
- Locations
- 🇩🇪
Praxis Dr. Steinebach, Essen, Essen, Germany
🇩🇪Praxis Dr. Pabst, Gilching, Gilching, Germany
🇩🇪Praxis Dr. Klein, Künzing, Künzing, Germany
Acute Caffeine Effects on Cardiac Autonomic and Cardiorespiratory Parameters Responses After Aerobic Exercise
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2016-09-30
- Target Recruit Count
- 35
- Registration Number
- NCT02917889
- Locations
- 🇧🇷
Universidade Estadual Paulista, Presidente Prudente, São Paulo, Brazil
The Effect of Caffeine on the Narcoleptic Patients
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- King Saud University
- Target Recruit Count
- 16
- Registration Number
- NCT02832336
- Locations
- 🇸🇦
King Khalid University Hospital:King Saud Medical City, Riyadh, Saudi Arabia
The Impact of Caffeine on Cognition in Schizophrenia
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 24
- Registration Number
- NCT02832401
- Locations
- 🇨🇦
BIOTIC Neuroimaging Laboratory, Halifax, Nova Scotia, Canada
This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 21
- Registration Number
- NCT02772601
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Berlin, Germany
Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Takeda
- Registration Number
- NCT02760615
- Locations
- 🇺🇸
WCCT, Cypress, California, United States
🇺🇸QPS MRA, Miami, Florida, United States
Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
- Conditions
- Interventions
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 17
- Registration Number
- NCT02740712
- Locations
- 🇵🇱
BioVirtus Research Site, Kajetany, Mokra 7, Poland
🇵🇱Zachodniopomorskie Centrum Onkologii Centrum Innowacji, Szczecin, Poland
🇵🇱Med Polonia, Poznan, Poland
Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02685462
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02655614
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, United States
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT02647086
- Locations
- 🇺🇸
Regeneron Study Site, Raleigh, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.